Top Medical Devices Stocks: Our 3 Picks for October 2026
A three-stock countdown explores medical devices through women’s-health diagnostics, orthopedic implants and robotic surgery, with valuation, profitability and earnings data for each company.

Medical devices stocks are caught between a challenged near-term narrative and durable long-term demand. The group has lagged broader healthcare as investors debate whether slower procedure growth, reimbursement pressure and pricing friction are cyclical or structural. Yet valuations have reset enough to make selective opportunities more interesting if execution improves. Abbott’s July 2026 earnings update, which included a higher full-year profit forecast on strength in diagnostics and medical devices, offered a timely reminder that company-specific performance can still overcome sector skepticism.
The structural case rests on aging populations, rising chronic disease prevalence and the shift toward minimally invasive care. Installed bases can also support recurring consumables, software and service revenue. Within the theme, structural heart, electrophysiology, robotics, diabetes devices, diagnostics and select surgical tools offer more compelling growth characteristics than commoditized categories facing heavier margin pressure. That makes product mix, procedure exposure and pricing power important differentiators when comparing companies.
This three-stock countdown focuses on companies with meaningful exposure to medical devices, then considers the business fundamentals supporting that exposure. The selections span women’s-health diagnostics, orthopedic reconstruction, robotic surgery and broader MedTech capabilities. We present the picks in countdown order from #3 to #1, with the strongest overall candidate appearing at the end.
Our screen was limited to US-listed companies with market capitalizations above $500 million and meaningful medical-device exposure. We ranked candidates first by the depth and relevance of that exposure, then by business fundamentals, including revenue and earnings growth, profitability, valuation, earnings consistency and composite quality metrics. The goal is not to treat every healthcare company as a pure-play device business, but to distinguish diversified groups with substantial MedTech operations from narrower or more commoditized exposures. This is a countdown: the best pick is revealed at #1.


